Pharmabiz

NIH-funded research shows oral small-molecule GLP-1 drugs penetrate deep into the brain to suppress cravings

NIH-funded research shows oral small-molecule GLP-1 drugs penetrate deep into the brain to suppress cravings: Bethesda, Maryland Saturday, May 9, 2026, 14:00 Hrs [IST] A National ...
Pharmabiz

Hongene Biotech shows advanced oligonucleotide CDMO capabilities via support of SiranBio’s dual-target siRNA programme

Hongene Biotech shows advanced oligonucleotide CDMO capabilities via support of SiranBio’s dual-target siRNA programme: Singapore Saturday, May 9, 2026, 16:00 Hrs [IST] Hongene ...
Pharmabiz

Nona Biosciences appoints Dr Josh Xiao as chief scientific officer to advance global scientific strategy and innovation

Nona Biosciences appoints Dr Josh Xiao as chief scientific officer to advance global scientific strategy and innovation: Cambridge, Massachusetts Saturday, May 9, 2026, 18:00 Hrs ...
Pharmabiz

RIVANNA receives US FDA 510(k) clearance for its Accuro XV musculoskeletal ultrasound imaging system

RIVANNA receives US FDA 510(k) clearance for its Accuro XV musculoskeletal ultrasound imaging system: Charlottesville, Virginia Saturday, May 9, 2026, 13:00 Hrs [IST] RIVANNA, a d ...
Pharmabiz

Altasciences and Certara ink strategic partnership to accelerate early drug development

Altasciences and Certara ink strategic partnership to accelerate early drug development: Laval, Quebec Saturday, May 9, 2026, 15:00 Hrs [IST] Altasciences, a fully integrated drug ...
Pharmabiz

Plus Therapeutics’ wholly owned subsidiary, CNSide Diagnostics receives Medicare enrollment approval

Plus Therapeutics’ wholly owned subsidiary, CNSide Diagnostics receives Medicare enrollment approval: Houston Saturday, May 9, 2026, 17:00 Hrs [IST] Plus Therapeutics, Inc., a h ...
Pharmabiz

Blackstone Life Sciences invests $250 mn in Anagram to advance novel oral enzyme replacement therapy for pancreatic insufficiency

Blackstone Life Sciences invests $250 mn in Anagram to advance novel oral enzyme replacement therapy for pancreatic insufficiency: Natick, Massachusetts Saturday, May 9, 2026, 12: ...
Pharmabiz

Indian pharma moving from volume-led generics to value plus innovation-led growth through strategic M&As

Experts have informed that the Indian pharma has moved from volume-led generics to value plus innovation-led growth through strategic mergers and acquisitions (M&As) over the past one year. The ...
Pharmabiz

Angelini Pharma to acquire Catalyst for 4.1 billion; entering US market and consolidating its leadership in brain health & rare disease

Angelini Pharma to acquire Catalyst for 4.1 billion; entering US market and consolidating its leadership in brain health & rare disease: Rome Saturday, May 9, 2026, 09:00 Hrs [IST ...
Pharmabiz

Oculis announces agreement with US FDA on a Special Protocol Assessment for optic neuritis registrational trial

Oculis announces agreement with US FDA on a Special Protocol Assessment for optic neuritis registrational trial: Zug, Switzerland Saturday, May 9, 2026, 11:00 Hrs [IST] Oculis Hol ...
Pharmabiz

Johnson & Johnson announces positive results from phase 3 FUZION study of Tremfya in perianal fistulizing Crohn's disease

Johnson & Johnson announced results from the phase 3 FUZION study evaluating Tremfya (guselkumab) in adults with active perianal fistulizing Crohn's disease (CD). At Week 24, Tremfya demonstrated ...
Pharmabiz

Breast implants: Hidden inflammation and later trouble, says study by Karl Landsteiner University

Hidden inflammation and later trouble, says study by Karl Landsteiner University: Krems, Austria Saturday, May 9, 2026, 10:00 Hrs [IST] A new study suggests that ...